CHOOSE TREMFYA®: THE FIRST AND ONLY LICENSED FULLY HUMAN IL-23p19 INHIBITOR, WITH EFFICACY AND SAFETY DATA OUT TO 5 YEARS*1-5

FIRST-LINE BIOLOGIC TREATMENT IN PSORIASIS1

TREMFYA® is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.1

Additional materials for your patients

Extra support for your patients: TREMFYA® guides, instruction downloads and information on the TREMFYA® Homecare Service

 

PATIENT RESOURCES ➔

MyTremfya for your patients

A patient support website with information about psoriasis, how TREMFYA® works and how to take it, extra support for self-injection, and answers to FAQs
 
VISIT THE WEBSITE ➔


*Includes a maintained Dermatology Life Quality Index (DLQI) and relief from itch, burning and pain improvements from baseline.3,4

REFERENCES

1. Janssen-Cilag Ltd. TREMFYA® Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc (last accessed: October 2020).
2. Griffiths CEM et al. Poster presented at: 37th Fall Clinical Dermatology Conference; October 18-21, 2018; Las Vegas, Nevada.
3. Blauvelt A et al. J Am Acad Dermatol 2017; 76(3):405–417.
4. Griffiths CEM et al. Poster presented at: 39th Fall Clinical Dermatology Conference; October 17-20, 2019; Las Vegas, Nevada.
5. Griffiths CEM et al. Poster presented at the 16th Annual Coastal Dermatology Symposium. October 15-16; 2020 New Jersey, USA.
6. Papp KA et al. Eur Acad Dermatol Venereol. 2018; 32(9):1515–1522.

 

Item Code: CP-186346
Date of Preparation: November  2020